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ABSTRACT 
The aim of this study was to identify the genetic defect in two patients having cardiac 
dysfunction accompanied by neurological symptoms, and in one case MRI evidence of 
cortical and cerebellar atrophy with hyperintensities in the basal ganglia. Muscle 
biopsies from each patient revealed single and combined mitochondrial respiratory 
chain deficiency. The complete mtDNA sequencing of both patients revealed two 
transitions in the mitochondrial tRNAVal gene (MT-TV) (m.1628C>T in patient 1, and 
m.1644G>A in patient 2). The functional and molecular analyses reported here suggest 
that the MT-TV gene should be routinely considered in the diagnosis of mitochondrial 
cardiomyopathies. 
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 Mitochondrial diseases (MDs) are a diverse group of disorders characterized by 
defects of the mitochondrial respiratory chain (DiMauro et al., 2008; Tucker et al., 
2010). These MDs can present at any age, and their clinical symptoms reflect a primary 
defect in tissues with high oxidative demand. The predominance of neuromuscular 
manifestations in MDs usually masks the presence of other clinical phenotypes, such as 
cardiac complications, but mitochondrial defects are being increasingly recognized to 
play a role in the pathogenesis of hereditary cardiomyopathies (Led et al., 2004). 
Sporadic or inherited mutations in mitochondrial DNA (mtDNA), specifically in the 
mtDNA transfer ribonucleic acid (tRNA) genes, or in the nuclear genome have been 
associated with hypertrophic and dilated cardiomyopathy (Papadopoulou et al., 1999; 
Hirano et al., 2001; Bénit et al., 2003; Taylor et al., 2003). Cardiac conduction 
abnormalities have also been associated with different mtDNA rearrangements (Marín-
García et al., 2002). Hence, the cardiac and neuromuscular manifestations of these 
mutations share common pathophysiological processes, and mitochondrial 
cardiomyopathies (MCMs) can be either heart-specific or associated with a spectrum of 
other symptoms (Led et al., 2004). However, heart-related manifestations in these 
patients are relatively mild compared to the severity of their neurological symptoms and 
the generalized muscle weakness that limits their activity. 
One of the first mtDNA point mutations associated with a maternally transmitted MCM 
and myopathy was described in 1991 (Zeviani et al., 1991), and the acronym MiMyCa 
was coined for this clinical syndrome. Since then, several mutations in the 
mitochondrial genome, mainly point mutations in mitochondrial tRNA (mt-tRNA) 
genes, have been associated with different MCM phenotypes (Hirano et al., 2001; 
Taylor et al., 2003.). In an attempt to identify mtDNA mutations associated with 
MCMs, we performed a systematic search in a series of patients that were suspected of 
MCM. As a result of this study, two transitions in the MT-TV gene were identified, the 
putative m.1628C>T mutation and the previously described, but not functionally 
characterized, m.1644G>A sequence variation (Tanji et al., 2008). In the present report, 
a selective reduction of the steady-state mt-tRNAVal level in the patient harbouring the 
m.1644G>A transition was found, confirming both the cardiac and the neurological 
involvement of this mutation.  
 
2. Material and methods 
2.1 Patient histories 
2.1.1 Patient 1 
 This 14-year-old boy was the sixth child of healthy and non-consanguineous 
Moroccan parents who had 7 children, all healthy except for one sister who died for of 
an unknown cause and another younger sister who presented short stature. Our patient 
presented short stature during the first years of life. At 9 years of age the parents 
observed palpebral ptosis, which required surgery. Physical examination revealed 
external ophthalmoplegia, pigmentary retinitis, and significant muscle atrophy in legs 
and arms. Cardiology study showed sinus rhythm and incomplete right bundle branch 
block in the electrocardiogram and mild hypertrophic cardiomyopathy in a transthoracic 
echocardiogram. Electromyogram showed a myopathic pattern. Serum laboratory 
parameters were normal. Likewise, urinary organic acids, plasma amino acids, and 
acylcarnitine profile were normal. Muscle biopsy was performed based on suspicion of 
a mitochondrial disorder. 
 
 
2.1.2 Patient 2 
 This 32-year-old man reported that since the age of 21 he had progressive 
gastrointestinal dysmotility, manifesting as episodic abdominal pain with diarrhea and 
progressive weight loss. At the same time, he developed progressive dementia, loss of 
balance, and a diagnosis of progressive encephalopathy was established. The patient 
was cachectic (weight: 42 kilograms, height: 175cm) and physical examination showed 
mild difficulty to walk, with tandem gait. Examination of cognitive functions, which 
were clearly impaired, was made difficult by behavioural abnormalities. He had 
generalized muscle weakness and sensory neuropathy in the extremities with absent 
tendon reflexes. Ten years later, he was referred to our center because of a new 
intestinal obstruction crisis, fever, refractory seizures, and loss of consciousness. He 
was admitted to the intensive care unit and a viral meningoencephalitis was suspected. 
The patient was infected with a respiratory Pseudomonas aeruginosa and the 
neurological situation became critical. His clinical condition progressed rapidly and he 
died of respiratory insufficiency 5 days later.  
Laboratory findings included normal serum creatine kinase, and high serum 
lactate (9.7mM; control values <2mM). The electrocardiogram revealed sinus rhythm 
and left bundle branch block, and the echocardiogram showed pronounced 
cardiomegaly and biventricular hypertrophy. Brain magnetic resonance imaging 
revealed mild diffuse cortical atrophy and severe cerebellar atrophy, and 
hyperintensities in the basal ganglia were found on T2 sequences. Muscle biopsy was 




2.2 Muscle histochemistry and enzyme activities of mitochondrial respiratory chain 
complexes 
 Samples from patients and controls were obtained in accordance with the 
Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from 
the families. The Ethics Committees of the 12 de Octubre Hospital and the Puerta de 
Hierro Hospital approved the study.  
 Quadriceps muscle biopsies were performed under local anesthesia. Serial 
frozen muscle sections were histochemically investigated for the presence of MD as 
described previously (Sciacco et al., 1996). Gomori trichrome and succinate 
dehydrogenase stains were used to detect ragged red fibers, and they were scored as 
positive when seen in >1% of all fibers. The cytochrome oxidase stain was used to 
detect complex IV activity. Respiratory chain complexes I-IV activities were measured 
in total muscle homogenates as described previously (Martinez et al., 2001), and related 
to those of citrate synthase (CS) to correct for mitochondrial volume.  
 
2.3 Mitochondrial DNA sequencing 
 Total genomic DNA was extracted from skeletal muscle by standard protocols. 
The complete mtDNA was amplified from total DNA in 24 overlapping 800–1000-bp-
long PCR fragments. Primers were carefully designed using the revised human 
mitochondrial DNA Cambridge reference sequence (Anderson et al., 1981; Andrews et 
al., 1999). The PCR fragments were sequenced on both strands using an ABI 3710 
(Applied Biosystems; Foster City, CA) sequencer and a dye terminator cycle 
sequencing kit (Applera, Rockville, MD).  
 
 
2.4 PCR/restriction fragment length polymorphism (RFLP) analysis  
 The level of the m.1628C>T and m.1644G>A heteroplasmy in the MT-TV gene 
were determined by the last-hot-cycle technique as described previously (Moraes et al., 
1993). To screen for the novel m.1628C>T transition, a 434-bp fragment was amplified 
by PCR using primers corresponding to nucleotide (nt) positions 1226-1245 (forward) 
and 1629-1660 (backward, primer mismatches in positions 1630 and 1633). PCR 
conditions were 95ºC for 30s, 61ºC for 30s, and 72ºC for 30s. After 35 cycles, 4 µCi of 
α32P-dCTP (2500 Ci/mmol) was added and a last cycle was performed. Aliquots (10 µl) 
of PCR products were digested with PvuII overnight and electrophoresed on a 15% non-
denaturing polyacrylamide gel. In wild type DNA, the enzyme cuts the 434 bp-PCR 
product into two fragments of 403-bp and 32-bp. The restriction site is absent when the 
m.1628C>T transition is present. For the m.1644G>A mutation, we used primers 
corresponding to nt positions 1585-1603 (forward) and 1757-1776 (backward) to PCR-
amplify a 192-bp fragment. In the presence of the mutation, this amplicon contains a 
restriction site for Tsp509I that produces two fragments of 133-bp and 59-bp. This 
restriction site is absent in the wild type molecule.  
 
2.5 Quantification of mitochondrial tRNAVal 
 mt-tRNAVal was quantified as described previously (Bornstein et al., 2005). 
Briefly, total RNA (5µg) extracted from skeletal muscle was incubated at 90°C for 5 
min, electrophoresed through a 12% polyacrylamide–7M urea gel and electroblotted 
onto a Zeta-probe membrane. Hybridization was performed at 42ºC for 24 h. The 
tRNAVal was detected using a synthetic 21-mer oligonucleotide (spanning mtDNA 
nucleotide positions 1669–1649), which had been labelled with [γ -32P] ATP at its 5-
end. This oligonucleotide probe does not encompass the mutated sites. After 
hybridization, the blot was washed and the membrane was stripped and rehybridized 
under the same conditions with a [γ -32P] 5-end-labelled 21-mer oligonucleotide 
corresponding to mtDNA positions 597–577 of the MT-TF gene. The ratio of tRNAVal 
to tRNAPhe was calculated by quantification of the respective signals by 
phosphorimager analysis. 
 
2.6 Cardiac evaluation  
 Cardiac study included standard 12-lead ECG and transthoracic two-dimensional 
echocardiogram.  Echocardiography was performed in the left lateral decubitus position 
using a Philips iE33 system (Philips Medical Systems, Eindhoven, The Netherlands). 
Standard techniques were used to obtain M-mode, two-dimensional, and Doppler 
measurements (Limongelli et al., 2010). The mean of three measurements was taken for 
each echocardiographic parameter. Patterns of hypertrophy were defined in accordance 
with previously published methods (Limongelli et al., 2010).  
 
3. Results 
3.1 Histochemical and biochemical studies 
 Muscle biopsy was performed based on suspicion of a mitochondrial disorder in 
both patients, and appeared normal both morphologically and histochemically. The 
activity of the different complexes of the mitochondrial respiratory chain (MRC) was 
assessed in muscle homogenates obtained from the biopsies. Patient 1 showed a single 
enzyme defect of complex I and an important increase in the activity of citrate synthase 
in his skeletal muscle. Patient 2 showed a combined enzyme defect of complexes I and 
IV of the MRC, and also a high citrate synthase activity in his skeletal muscle (Table 1).  
 
3.2 Sequencing and PCR-RFLP analyses 
 In order to identify putative mutations in the mitochondrial genome, we purified 
and completely sequenced the mtDNA obtained from skeletal muscle of both patients. 
Sequence analysis revealed a total of 49 nucleotide changes from the revised Anderson 
mtDNA sequence in patient 1 (Suppl Table 1A) (Anderson et al., 1981; Andrews et al., 
1999). Haplogroup analysis showed the African origin of this subject, belonging to 
mitochondrial haplogroup L2a1. All sequence variations identified in this patient were 
previously described polymorphisms or synonymous substitutions within expressed 
sequences, except for the m.1628C>T transition identified in the MT-TV gene. This mt-
variant was shown to be homoplasmic, involving all copies of the mtDNA in skeletal 
muscle from patient 1 (Figure 1A).  
 On the other hand, complete sequencing of the mtDNA from patient 2 revealed 
35 sequence variations from the revised Anderson mtDNA sequence (Suppl Table 1B), 
and indicated that this patient has a European origin (haplogroup X2b). Among the 35 
mitochondrial variations, a previously described mutation, the m.1644G>A mutation in 
the MT-TV gene, was identified (Tanji et al., 2008). This sequence change was found in 
heteroplasmy, and the patient harboured 94.4% mutant mtDNA in his skeletal muscle 
(Figure 1B).  
 Since this is a retrospective study, we could not verify the presence of the two 
transitions in other tissues from each of the two patients, and therefore we could not 
determine the heteroplasmy percentages of the mutated MT-TV gene in cardiac muscle, 
which may have given indications about the likely pathogenicity of these mt-variations.  
 
3.3. Mitochondrial tRNAVal steady-state levels  
 In order to study the potential pathogenicity of both mutations we decided to 
investigate the steady-sate level of tRNAVal. Unfortunately, this study could only be 
carried out for the m.1644G>A mutation, because of we ran out of muscle tissue of 
patient 1. Total RNA was extracted from a muscle sample of patient 2 and from two 
control samples, and resolved by polyacrylamide gel electrophoresis. After electro-
blotting, the membrane was hybridized to specific mt-tRNAVal or control 
oligonucleotide probes as described in the Material and Methods section. Figure 2 
shows the ratio of mt-tRNAVal to mt-tRNAPhe in patient 2 and control muscle samples. 
Quantitative analysis of the autoradiograms showed a significant 67% decrease in the 
steady-state level of the tRNAVal harbouring the m.1644G>A mutation as compared to 
control samples (Figure 2).  
 
4. Discussion 
 In this report, the clinical, histochemical, biochemical, and molecular diagnosis 
of two patients with suspected heart defect as a consequence of MD is described. This 
study revealed two different nucleotide variants in the MT-TV gene: m.1628C>T and 
m.1644G>A. A growing number of mitochondrial cardiomyopathies are found to be 
associated with point mutations in the mt-tRNA genes, especially MT-TL1, MT-TI, and 
MT-TK (Marín-García et al., 2000; Led et al., 2004; Wahbi et al., 2010). MDs caused by 
mutations in the MT-TV gene are not very frequent, but three of the seven point 
mutations described so far in this gene (Figure 3) have been associated with 
hypertrophic cardiomyopathy or severe cardiac failure (Chalmers et al., 1997; 
McFarland et al., 2002; Blakely et al., 2004). In accordance with these three reported 
cases, our two patients developed cardiac conduction abnormalities and hypertrophic 
cardiomyopathy within a neurological presentation, and because of this, together with 
radiographic findings, MD was suspected in both cases. Muscle biopsies did not 
confirm the clinical impression of MD as they were morphologically and 
histochemically normal in the two patients, in contrast with biopsy findings of patients 
with mutations in the MT-TV gene previously described (Chalmers et al., 1997; Tiranti 
et al., 1998; Sacconi et al., 2002; McFarland et al., 2002; Tanji et al., 2008; Horváth et 
al., 2009; Yan et al., 2010). On the other hand, biochemical analysis showed a decrease 
in MRC complex I activity in muscle homogenate from patient 1, and a combined 
deficiency in the activity of MRC complexes I and IV from patient 2, as in most 
previous reports on mutations in the MT-TV gene (Chalmers et al., 1997; Tiranti et al., 
1998; Sacconi et al., 2002; McFarland et al., 2002; Tanji et al., 2008; Horváth et al., 
2009; Yan et al., 2010). 
Complete sequencing of the mtDNA from muscle of patient 1 allowed us to identify a 
homoplasmic m.1628C>T transition in the MT-TV gene. Although the presence of 
heteroplasmy is a common pathogenic criterion for mt-tRNA mutations (McFarland et 
al., 2004), homoplasmic mutations, as is the case of the m.1628C>T transition, are 
being increasingly recognized as causes of MD (McFarland et al., 2002; DiMauro, 
2006; DiMauro, 2011). Although funcional analysis of this mutation was not possible 
due to the lack of sample, molecular data support that this nucleotide variation could be 
relevant from a functional point of view. Supporting data include: (i) the mutation is 
associated with a mitochondrial phenotype of hypertrophic cardiomyopathy with 
palpebral ptosis, external ophthalmoplegia, pigmentary retinitis, and muscle atrophy; 
(ii) a single enzyme deficiency of MRC complex I and an increase in the activity of 
citrate synthase in skeletal muscle; (iii) the mutation involves a C to T change in the 
anticodon-stem of the MT-TV gene, which might interrupt the secondary structure of the 
anticodon-stem; (iv) mitochondrial nucleotide 1628 is quite conserved through 
evolution (Sprinzl et al., 1989; McFarland et al., 2004), suggesting that the m.1628C>T 
sequence variation may have a functional consequence; (v) this mutation was identified 
only once in a total of more than 4000 mtDNA sequences from public databases 
(Ingman and Gyllensten, 2003) and in more than 600 mtDNA sequences from our 
laboratory, which include controls and samples from a wide spectrum of pathological 
conditions associated to mitochondrial dysfunctions; and vi) as an indication for 
suspecting its pathogenic character, the other sample in which the m.1628C>T sequence 
variation was identified corresponds to a different haplogroup (haplogroup HV) 
(Torroni et al., 2003; Gallardo et al., 2006; DiMauro, 2011). In consequence, we 
propose that, in the absence of functional studies, the m.1628C>T transition in the MT-
TV gene is  a good candidate to be responsible for the clinical phenotype observed in 
patient 1.  
 In patient 2, the heteroplasmic m.1644G>A transition was identified in skeletal 
muscle. Besides cardiac dysfunction, neurogastrointestinal manifestations were the 
main clinical phenotype in this patient. Gastrointestinal dismotility is not usually 
associated with mt-tRNA mutations, but it has been described in patients with MELAS 
caused by the mtDNA point mutation m.3243A>G (Shimotake et al., 1998; García-
Velasco et al., 2003). Recently, the m.1630A>G mutation in the MT-TV gene was 
reported in a child with MNGIE-like disease (Horváth et al., 2009). On the other hand, 
the m.1644G>A mutation was recently described in another patient, but with a different 
clinical phenotype (Tanji et al., 2008). Our patient presented a more severe clinical 
phenotype, including cardiac involvement, which was absent in the aforementioned case 
report; this could be due to a higher heteroplasmy percentage in the muscle of our 
patient (94.4%) compared to that observed in the previously described patient (85%) 
(Tanji et al., 2008). In addition, it is worth mentioning that the heteroplasmy percentage 
is higher in skeletal muscle of patients with MCMs and mutations in the MT-TV gene 
(Chalmers et al., 1997; McFarland et al., 2002; Blakely et al., 2004) than in patients 
without heart defects and mutations in the same gene (Taylor et al., 1996; De Coo et al., 
1998; Tiranti et al., 1998; Sacconi et al., 2002; Tanji et al., 2008; Horváth et al., 2009). 
Hence, mutant levels in skeletal muscle above 94% are probably required to affect the 
cardiac muscle in patients with MD associated with mutations in the MT-TV gene 
(Table 2). 
 To unravel the pathogenic mechanism of the m.1644G>A mutation, the 
mitochondrial tRNAVal steady state levels were studied. As shown in Figure 2, there 
was a marked and selective reduction of the steady-state mt-tRNAVal level as compared 
to mt-tRNAPhe in skeletal muscle from patient 2 (27% of control values). Recent studies 
by us and others have shown that a decreased level of different mt-tRNAs inhibit 
mitochondrial protein synthesis (Enriquez et al., 1995; McFarland et al., 2002; 
Bornstein et al., 2005). Accordingly, patient 2 presents a strong reduction in complex I 
and IV activities in muscle homogenate. Moreover, our data are consistent with the 
m.1644G>A mt-tRNAVal being rapidly degraded. To date, the most pronounced 
decrease of the steady-state mt-tRNAVal in cardiac and in skeletal muscles has been 
observed in the presence of the mutation m.1624C>T (McFarland et al., 2002). This 
mutation, affecting the same mt-gene, is associated with infantile and fatal Leigh 
syndrome together with severe cardiac failure in one of ten children affected 
(McFarland et al., 2002). Interestingly, tissues from all members of this pedigree were 
homoplasmic for the m.1624C>T mutation, as is the m.1628C>T transition in the 
skeletal muscle of patient 1 in our study. However, the marked variability in phenotype 
among different family members can not be explained by this mtDNA defect alone 
(Rorbach et al., 2008). Our patient 2 had no known maternal family diagnosed of MD, 
and we could not confirm the presence of a low level mt-tRNAVal in cardiac muscle or 
in tissues from other maternal relatives. In addition, conformational changes or 
aminoacylation defects have also been found in other mt-tRNA point mutations as 
potential pathogenic mechanisms responsible for different clinical phenotypes 
(Enriquez et al., 1995; Bacman et al., 2003; Florentz et al., 2003; Bornstein et al., 2005). 
In our case, there was insufficient muscle sample and it could not be confirmed whether 
this mutation may also lead to a conformational change or impaired aminoacylation 
capacity of the mt-tRNAVal.  
 In conclusion, the two cases presented in this report reinforce the notion that 
cardiac manifestations are frequent in patients with mitochondrial disorders. Therefore, 
cardiac evaluation should be routinely performed at the time of diagnosis of MD in 
these patients. This study also shows that mitochondrial tRNA mutations associated 
with heart disease not only involve the leucine, lysine, or isoleucine tRNA genes, and 
that the mitochondrial valine tRNA gene should be sequenced when there is a high 
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Fig. 1. PCR-RFLP analyses of the mutations. PCR-amplified and radiolabeled 
mtDNA fragments were digested, separated by gel electrophoresis, exposed to a 
phosphorimager plate for 24 h, and analyzed with image-quant software. Panel A: 
PCR-RFLP analysis of the m.1628C>T transition. Amplified fragments of 435-bp are 
cut into 403-bp and 32-bp fragments after digestion with PvuII when harboring the 
wild-type molecule. Lanes: 1, uncut band control muscle; 2, cut band control muscle; 3, 
uncut band patient 1 muscle; 4, cut band patient 1 muscle. Panel B: PCR-RFLP 
analysis of the m.1644G>A mutation. Amplified fragments of 192-bp are cut into 133-
bp and 59-bp fragments after digestion with Tsp509I when harboring the m.1644G>A 
mutation. Lanes: 1, uncut band control muscle; 2, cut band control muscle; 3, uncut 
band patient 2 muscle; 4, cut band patient 2 muscle. 
 
 
Fig. 2. Steady-state levels of tRNAVal in muscle from controls and patient 2. 
Total RNA extracted from skeletal muscle was analysed by Northern blotting using 
specific tRNAVal and tRNAPhe probes. Equal amounts of RNA (5 µg) were fractionated 
on 12% polyacrylamide-7M urea gels, transferred onto a nylon membrane, hybridized 
with the tRNAVal and tRNAPhe radiolabelled probes, and autoradiographed (left panels). 
Lane1, patient 1 RNA; Lane 2, control RNA 1; Lane 3, control RNA 2. Signals from 
two independent experiments for each sample were quantified by phosphoimager 
readings. The steady-state levels of tRNAVal normalized against tRNAPhe are shown on 
the right. Val/Phe-1, Val/Phe-2, and Val/Phe-3 correspond to the ratios of tRNAVal and 
tRNAPhe shown in the left hand panels in lanes 1, 2, and 3, respectively. 
 Fig. 3. Schematic representation of the mt-tRNAVal cloverleaf structure. Three sets 
of pathogenic mutations associated with MCMs are highlighted in red. The two 
mutations identified in the present study are highlighted in green. Other known 
mutations in the same mitochondrial tRNAVal but not related with MCM are also 
indicated.  
 
 
 
 
 
 
 
 
